86 related articles for article (PubMed ID: 21168669)
1. Effects of cyclooxygenase-2 inhibitor and adenosine triphosphate-sensitive potassium channel opener in syngeneic mouse islet transplantation.
Juang JH; Kuo CH
Transplant Proc; 2010 Dec; 42(10):4221-4. PubMed ID: 21168669
[TBL] [Abstract][Full Text] [Related]
2. Induction of beta-cell rest by a Kir6.2/SUR1-selective K(ATP)-channel opener preserves beta-cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose.
Ritzel RA; Hansen JB; Veldhuis JD; Butler PC
J Clin Endocrinol Metab; 2004 Feb; 89(2):795-805. PubMed ID: 14764798
[TBL] [Abstract][Full Text] [Related]
3. NN414, a SUR1/Kir6.2-selective potassium channel opener, reduces blood glucose and improves glucose tolerance in the VDF Zucker rat.
Carr RD; Brand CL; Bodvarsdottir TB; Hansen JB; Sturis J
Diabetes; 2003 Oct; 52(10):2513-8. PubMed ID: 14514634
[TBL] [Abstract][Full Text] [Related]
4. Openers of ATP-dependent K+-channels protect against a signal-transduction-linked and not freely reversible defect of insulin secretion in a rat islet transplantation model of Type 2 diabetes.
Björklund A; Bondo Hansen J; Falkmer S; Grill V
Diabetologia; 2004 May; 47(5):885-91. PubMed ID: 15088085
[TBL] [Abstract][Full Text] [Related]
5. Attenuation of hyperinsulinemia by NN414, a SUR1/Kir6.2 selective K-adenosine triphosphate channel opener, improves glucose tolerance and lipid profile in obese Zucker rats.
Alemzadeh R; Fledelius C; Bodvarsdottir T; Sturis J
Metabolism; 2004 Apr; 53(4):441-7. PubMed ID: 15045689
[TBL] [Abstract][Full Text] [Related]
6. Exendin-4 treatment expands graft beta-cell mass in diabetic mice transplanted with a marginal number of fresh islets.
Juang JH; Kuo CH; Wu CH; Juang C
Cell Transplant; 2008; 17(6):641-7. PubMed ID: 18819252
[TBL] [Abstract][Full Text] [Related]
7. Harnessing the Foreign Body Reaction in Marginal Mass Device-less Subcutaneous Islet Transplantation in Mice.
Pepper AR; Pawlick R; Bruni A; Gala-Lopez B; Wink J; Rafiei Y; Bral M; Abualhassan N; Shapiro AM
Transplantation; 2016 Jul; 100(7):1474-9. PubMed ID: 27136258
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of angiogenesis is associated with reduced islet engraftment in diabetic recipient mice.
Zhang N; Qu S; Xu J; Bromberg JS; Dong HH
Transplant Proc; 2005 Dec; 37(10):4452-7. PubMed ID: 16387144
[TBL] [Abstract][Full Text] [Related]
9. Reduction in primary nonfunction of syngeneic islet transplants with nordihydroguaiaretic acid, a lipoxygenase inhibitor.
Hsu BR; Juang JH; Fu SH; Kuo CH; Lu WT
Cell Transplant; 2001; 10(3):255-62. PubMed ID: 11437071
[TBL] [Abstract][Full Text] [Related]
10. Influence of donor age on mouse islet characteristics and transplantation.
Juang JH; Hsu BR; Kuo CH; Yaot NK
Cell Transplant; 2001; 10(3):277-84. PubMed ID: 11437073
[TBL] [Abstract][Full Text] [Related]
11. Triptolide prolonged allogeneic islet graft survival in chemically induced and spontaneously diabetic mice without impairment of islet function.
Xin MJ; Cui SH; Liu S; Sun HC; Li F; Sun JB; Luo B
Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):312-8. PubMed ID: 20525560
[TBL] [Abstract][Full Text] [Related]
12. Long-term insulin independence following repeated islet transplantation in totally pancreatectomized diabetic pigs.
Morsiani E; Fogli L; Lanza G; Lebow LT; Demetriou AA; Rozga J
Cell Transplant; 2002; 11(1):55-66. PubMed ID: 12095221
[TBL] [Abstract][Full Text] [Related]
13. Beta cell mass and growth after syngeneic islet cell transplantation in normal and streptozocin diabetic C57BL/6 mice.
Montaña E; Bonner-Weir S; Weir GC
J Clin Invest; 1993 Mar; 91(3):780-7. PubMed ID: 8450059
[TBL] [Abstract][Full Text] [Related]
14. Possible New Strategies for the Treatment of Congenital Hyperinsulinism.
Sikimic J; Hoffmeister T; Gresch A; Kaiser J; Barthlen W; Wolke C; Wieland I; Lendeckel U; Krippeit-Drews P; Düfer M; Drews G
Front Endocrinol (Lausanne); 2020; 11():545638. PubMed ID: 33193079
[TBL] [Abstract][Full Text] [Related]
15. Improved outcome of islet transplantation in insulin-treated diabetic mice: effects on beta-cell mass and function.
Merino JF; Nacher V; Raurell M; Aranda O; Soler J; Montanya E
Diabetologia; 1997 Sep; 40(9):1004-10. PubMed ID: 9300236
[TBL] [Abstract][Full Text] [Related]
16. Islet transplantation at subcutaneous and intramuscular sites.
Juang JH; Hsu BR; Kuo CH
Transplant Proc; 2005 Oct; 37(8):3479-81. PubMed ID: 16298634
[TBL] [Abstract][Full Text] [Related]
17. Prevention of primary islet isograft nonfunction in mice with pravastatin.
Arita S; Une S; Ohtsuka S; Atiya A; Kasraie A; Shevlin L; Mullen Y
Transplantation; 1998 Jun; 65(11):1429-33. PubMed ID: 9645797
[TBL] [Abstract][Full Text] [Related]
18. Transplantation of islet tissue in the rat.
Hegre OD; Leonard RJ; Erlandsen SL; McEvoy RC; Parsons JA; Elde RP; Lazarow A
Acta Endocrinol Suppl (Copenh); 1976; 205():257-81. PubMed ID: 826063
[TBL] [Abstract][Full Text] [Related]
19. The effects of NN414, a SUR1/Kir6.2 selective potassium channel opener in subjects with type 2 diabetes.
Zdravkovic M; Kruse M; Rost KL; Møss J; Kecskes A
Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):405-6. PubMed ID: 17701889
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice.
Merani S; Truong W; Emamaullee JA; Toso C; Knudsen LB; Shapiro AM
Endocrinology; 2008 Sep; 149(9):4322-8. PubMed ID: 18511515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
